세계의 산화 스트레스 분석 시장(2024-2031년)

Global Oxidative Stress Assay Market Size, Share & Trends Analysis Report by Product (Instruments, Consumables, and Services), by Test Type (Indirect Assays, Antioxidant Capacity Assays, Enzyme Assays, and Reactive Oxygen Species Assays) by Technology (Enzyme-Linked Immunosorbent Assay (ELISA), Flow Cytometry, Chromatography, Microscopy, and Others) by Disease Type (Cardiovascular Disease, Chronic Obstructive Pulmonary Disease (COPD), Cancer, Respiratory Diseases, Diabetes, and Other) and by End User (Pharmaceutical and Biotechnology Industries, Academic Research institutes, and Clinical Research Organizations) Forecast Period (2024-2031)

The global oxidative stress assay market is anticipated to grow at a CAGR of 8.3% during the forecast period (2024-2031). The global oxidative stress assay market is influenced by various factors, including the increasing prevalence of chronic diseases, the aging population, environmental factors, and the shift toward personalized medicine. Chronic diseases, such as cancer, cardiovascular diseases, diabetes, and neurodegenerative disorders, are more susceptible to oxidative stress due to reduced antioxidant defense mechanisms. The aging population is additionally more susceptible to oxidative stress due to increased exposure to pollutants and toxins. The shift towards personalized medicine has fueled the demand for biomarker-based assays, enabling healthcare providers to tailor treatment strategies based on individual patient characteristics. Technological advancements have improved the sensitivity, specificity, and accuracy of oxidative stress measurements. Regulatory support from agencies like the FDA and EMA encourages adoption in healthcare settings. Awareness campaigns and collaborations between academic institutions, research organizations, and biotechnology companies further drive market growth.

Market Dynamics

Increased Susceptibility to Oxidative Stress

The aging leads to decreased antioxidant defenses, increasing oxidative stress-related conditions. As the aging population grows, the demand for oxidative stress assays increases for early detection and monitoring. According to the Centers for Disease Control and Prevention (.gov), in September 2022, the aging population in the US has reached unprecedented levels, with $54.1 million adults aged 65 or older in 2019, accounting for 16.0% of the population. By 2040, it is projected that this number will increase to $80.8 million, and by 2060, it will reach $94.7 million, comprising almost 25.0% of the total population. With age, the risk of chronic diseases such as dementia, heart disease, type 2 diabetes, arthritis, and cancer also increases, leading to significant healthcare costs and societal implications.

Rising Public Health Initiatives and Government Policies

Governments and international organizations are investing in public health initiatives to address chronic diseases and improve healthcare infrastructure. Integrating oxidative stress assays into national health programs supports evidence-based policymaking and stimulates market growth. According to the World Health Organization (WHO), in December 2023, global health spending reached a new high of $9.8 trillion, accounting for 10.3% of GDP. However, the distribution of spending remained unequal, with public spending increasing globally, except in low-income countries where government spending decreased. Low-income countries accounted for only 0.24% of global health expenditure.

Market Segmentation

Our in-depth analysis of the global oxidative stress assay market includes the following segments by product, test type, technology, disease type, and end-user:

• Based on product, the market is sub-segmented into instruments, consumables, and services.
• based on test type, the market is sub-segmented into indirect assays, antioxidant capacity assays, enzyme-based assays, and reactive oxygen species-based assays.
• Based on technology, the market is bifurcated into Enzyme-Linked Immunosorbent Assay (ELISA), flow cytometry, chromatography, microscopy, and others.
• Based on disease type, the market is bifurcated into cardiovascular disease, Chronic Obstructive Pulmonary Disease (COPD), cancer, respiratory diseases, diabetes, and other (neurodegenerative diseases).
• Based on end-users, the market is sub-segmented into pharmaceutical and biotechnology industries, academic research institutes, and clinical research organizations.

Pharmaceutical and Biotechnology Industries is Projected to Emerge as the Largest Segment

Based on the business model, the global oxidative stress assay market is sub-segmented into pharmaceutical and biotechnology industries, academic research institutes, and clinical research organizations. Among these, the advertising-supported model sub-segment is expected to hold the largest share of the market. The primary factor supporting the segment's growth includes the pharmaceutical and biotechnology industries are experiencing growth owing to reduced taxes, lower drug prices, and economic growth in regions such as the US, China, and India, leading to increased investment in R&D. According to the National Center for Biotechnology Information, in March 2021, it reduced taxes and lowered drug prices in the US, a gross domestic product growth greater than 6.0% in China and India, widespread population aging and sedentary lifestyles leading to increased chronic diseases, industrialized data services in R&D enabling the use of clinical trial data in trial simulations, lowered regulatory barriers for new drugs in the US, and high urban pollution levels increasing the incidence of conditions such as asthma, have contributed to the growth of the healthcare market.

Cancer Sub-segment to Hold a Considerable Market Share

The oxidative stress assay market is experiencing growth owing to the rise in cancer incidence and demand for innovative diagnostic solutions. Advancements in assay platforms, screening methodologies, and data analytics enhance their sensitivity and specificity. According to the American Cancer Society, in 2022, it is projected approximately $1.9 million new cases of cancer diagnosed and an estimated 609,360 fatalities caused by cancer in the US.

Regional Outlook

The global oxidative stress assay market is segmented based on geography including North America (the US, and Canada), Europe (the UK, Italy, Spain, Germany, France, and the Rest of Europe), Asia-Pacific (India, China, Japan, South Korea, and Rest of Asia-Pacific), and the Rest of the World (the Middle East & Africa, and Latin America).

Investment in Healthcare Infrastructure in the Asia-Pacific Region

A growing emphasis on improving healthcare infrastructure, especially in developing countries such as India for enhanced diagnostic services and market expansion, is highlighted by the rise in health expenditure and PMABHIM operations. According to the Healthcareradius.in, February 2024, the total expenditure on health has seen a significant increase, rising from $9.5 billion in 2023-24 to $10.9 billion in 2024-25. In addition, the allocation for the Pradhan Mantri Ayushman Bharat Health Infrastructure Mission (PMABHIM) has also experienced a substantial boost, going up from $2.5 in 2023-24 to $49.7 in 2024-25.

North America Holds Major Market Share

The US oxidative stress assay market is expanding owing to the R&D investment in the US, international collaborations, strategic partnerships, and technological innovation. This market is influencing global healthcare needs and growth. According to the National Center for Science and Engineering Statistics (.gov), in April 2022, the US research and experimental development performance experienced significant growth in recent years, with the total reaching $667.0 billion in 2019 and an estimated $708.0 billion in 2020. This growth was observed across all sectors, particularly in the business sector. Additionally, the US national R&D intensity, a measure of R&D investment, has shown a steady increase, reaching 3.39% in 2020.

The major companies serving the global oxidative stress assay market include Abcam Ltd., Cell Biolabs, Inc. Merck KGaA, Promega Corp., and Thermo Fisher Scientific Inc. among others. The market players are increasingly focusing on business expansion and product development by applying strategies such as collaborations, mergers, and acquisitions to stay competitive in the market. For instance, in February 2022, Invitae launched the availability of FusionPlex Dx and LiquidPlex Dx in Europe, part of its industry-leading Anchored Multiplex PCR chemistry in-vitro diagnostic (IVD) products. Invitae is delivering essential high-quality innovation for precision oncology in the fight against cancer.

Table of Contents

1. Report Summary

• Current Industry Analysis and Growth Potential Outlook
• 1.1. Research Methods and Tools
• 1.2. Market Breakdown
  • 1.2.1. By Segments
  • 1.2.2. By Region

2. Market Overview and Insights

• 2.1. Scope of the Report
• 2.2. Analyst Insight & Current Market Trends
  • 2.2.1. Key Industry Trends
  • 2.2.2. Recommendations
  • 2.2.3. Conclusion

3. Competitive Landscape

• 3.1. Key Company Analysis
• 3.2. Abcam Ltd.
  • 3.2.1. Overview
  • 3.2.2. Financial Analysis
  • 3.2.3. SWOT Analysis
  • 3.2.4. Recent Developments
• 3.3. Merck KGaA
  • 3.3.1. Overview
  • 3.3.2. Financial Analysis
  • 3.3.3. SWOT Analysis
  • 3.3.4. Recent Developments
• 3.4. Promega Corp.
  • 3.4.1. Overview
  • 3.4.2. Financial Analysis
  • 3.4.3. SWOT Analysis
  • 3.4.4. Recent Developments
• 3.5. Key Strategy Analysis

4. Market Segmentation

• 4.1. Global Oxidative Stress Assay Market by Product
  • 4.1.1. Instruments
  • 4.1.2. Consumables
  • 4.1.3. Services
• 4.2. Global Oxidative Stress Assay Market by Test Type
  • 4.2.1. Indirect assays
  • 4.2.2. Antioxidant capacity assays
  • 4.2.3. Enzyme-based assays
  • 4.2.4. Reactive Oxygen species based assays
• 4.3. Global Oxidative Stress Assay Market by Technology
  • 4.3.1. Enzyme-linked Immunosorbent Assay (ELISA)
  • 4.3.2. Flow Cytometry
  • 4.3.3. Chromatography
  • 4.3.4. Microscopy
  • 4.3.5. Others (Nuclear Magnetic Resonance (NMR) Spectroscopy, and Spectrophotometry)
• 4.4. Global Oxidative Stress Assay Market by Disease Type
  • 4.4.1. Cardiovascular disease
  • 4.4.2. Chronic Obstructive pulmonary disease (COPD)
  • 4.4.3. Cancer
  • 4.4.4. Respiratory Diseases
  • 4.4.5. Diabetes
  • 4.4.6. Others (Inflammatory Diseases, Neurological Disorders)
• 4.5. Global Oxidative Stress Assay Market by End-user
  • 4.5.1. Pharmaceutical and Biotechnology Industries
  • 4.5.2. Academic Research Institutes
  • 4.5.3. Clinical Research Organizations

5. Regional Analysis

• 5.1. North America
  • 5.1.1. United States
  • 5.1.2. Canada
• 5.2. Europe
  • 5.2.1. UK
  • 5.2.2. Germany
  • 5.2.3. Italy
  • 5.2.4. Spain
  • 5.2.5. France
  • 5.2.6. Rest of Europe
• 5.3. Asia-Pacific
  • 5.3.1. China
  • 5.3.2. India
  • 5.3.3. Japan
  • 5.3.4. South Korea
  • 5.3.5. Rest of Asia-Pacific
• 5.4. Rest of the World
  • 5.4.1. Latin America
  • 5.4.2. Middle East & Africa

6. Company Profiles

• 6.1. AMSBIO
• 6.2. Arbor Assays, Inc.
• 6.3. Cayman Chemical Co.
• 6.4. Cell Biolabs, Inc.
• 6.5. Enzo Biochem, Inc.
• 6.6. Enzo Life Sciences, Inc.
• 6.7. F. Hoffmann-La Roche Ltd.
• 6.8. Antibodies Inc.
• 6.9. OXFORD BIOMEDICAL RESEARCH
• 6.10. QIAGEN
• 6.11. Sekisui Diagnostics, LLC.
• 6.12. StressMarq Biosciences Inc.
• 6.13. Thermo Fisher Scientific Inc.
• 6.14. KAMIYA BIOMEDICAL CO.